Traders Brace for Japan's 40-Year Bond Sale After Yields Swoon
Investors are on tenterhooks Wednesday for an auction of 40-year Japanese government bonds as volatility in the nation's yields continues to rumble through global debt markets.
The sale is seen as a key test for longer-maturity bonds amid concern from Tokyo to New York that rising government spending will take budget deficits into dangerous territory. The challenges in Japan's bond market are amplified by the central bank rolling back its purchases and reluctance of institutional investors to fill the gap.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Semler Scientific, Inc. (SMLR) Faces Scrutiny from Edelson Lechtzin LLP
On June 4, 2025, Edelson Lechtzin LLP announced that it has initiated an inquiry into whether the healthcare technology company, Semler Scientific, Inc. (NASDAQ:SMLR), misled investors about its business operations regarding claims tied to its QuantaFlo diagnostic device. A doctor in focus surrounded by colleagues in a hospital setting. In an annual report filed by Semler Scientific, Inc. (NASDAQ:SMLR) on February 28, 2025, the company disclosed that the U.S. Department of Justice (DOJ) was evaluating a potential False Claims Act case. The report triggered immediate market reaction, with the company's shares plummeting by 9.4% to close at $38.89 on March 3. Initiating the inquiry, Edelson Lechtzin LLP has asked for the public and stakeholders' help. Edelson urges those with non-public information regarding Semler Scientific, Inc. (NASDAQ:SMLR) to come forward and assist them in the investigation. It also encourages the company's investors who have suffered losses to follow the inquiry to learn more. The investor confidence has been significantly fluctuating since the disclosure. The stock's performance, which gained 6.49% last month, declined by 13.46% last week. The California-based company, Semler Scientific, Inc. (NASDAQ:SMLR), is known for developing non-invasive medical tools, with QuantaFlo being its most prominent product. Focusing on early disease detection and chronic condition management, the company has positioned itself between healthcare and technology. While we acknowledge the potential of SMLR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Sign in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
UBS Lifts Kingsoft Cloud Holdings Limited (KC) to $14 Amid AI Growth
On Thursday, UBS analysts raised the price target for Kingsoft Cloud Holdings Limited (NASDAQ:KC) while maintaining a "Buy" rating. This confidence is attributed to the company's position as a pure-play cloud vendor with huge AI potential, anticipated to increase to over 40% by 2027, in contrast to 17% of total revenue in 2024. An executive standing in front of their headquarters building, proudly symbolizing the company's achievements. A fascinating development is the anticipated rebound in the company's public cloud segment, which is projected to achieve a 20% revenue compound annual growth rate (CAGR) by 2027. From the climbing demand for AI-powered cloud solutions, greater contributions from Xiaomi's ecosystem, and sustained growth in external clients, the reasons that explain this surge are many. Analysts also anticipate that Kingsoft Cloud Holdings Limited's (NASDAQ:KC) non-GAAP operating margin will improve, with narrow losses expected until achieving profitability by 2027. This strengthened standing is driven by higher revenue dependence on AI and enhanced cost efficiency from scaling operations. Indeed, it's AI that is backing the analysts' bullish stance. Kingsoft Cloud Holdings Limited (NASDAQ:KC) is a Chinese cloud service provider that offers cloud solutions, research and development services, enterprise digital solutions, and related services. Founded in 2012, the company aims to become clients' trusted partners and capitalize on digitalization. While we acknowledge the potential of KC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Eli Lilly (LLY)'s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating
On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT trial. TD Cowen's analysis demonstrates that LLY's tirzepatide needs to match a MACE hazard ratio of 0.9 or better to statistically outperform dulaglutide. A scientist in a lab running tests on a variety of biopharmaceuticals. The investment firm hosted a survey of key opinion leaders, where 92% of the participants said they estimate a hazard ratio of 0.85 or better. Despite the positive outlook among survey respondents, investors remain wary about the possibility of attaining superiority over dulaglutide. Analysts also reworked their financial model for Eli Lilly and Company (NYSE:LLY) after the latest company updates and the Q1 2025 results. The 2026 EPS figures have been trimmed to $29.15, down by $0.25. The stock is now trading at a P/E ratio of 62.07, implying strong growth estimates. Eli Lilly and Company (NYSE:LLY) is a major global pharma giant based in Indianapolis that develops and commercializes medicines for diabetes, cancer, obesity, and autoimmune diseases. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
